Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a third chemo drug tame advanced endometrial cancer?

NCT ID NCT06102252

Disease control Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding a drug called epirubicin to the standard two-drug chemotherapy (paclitaxel and carboplatin) helps people with advanced endometrial cancer. Sixty patients were enrolled to see if the three-drug combo is better at controlling the disease before surgery. The main goal was to see how many patients could complete all six cycles of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Paclitaxel, carboplatin, and epirubicin (chemotherapy drugs)
What this could lead to
If adding epirubicin works better, it could improve how well chemotherapy shrinks advanced endometrial cancer before surgery.
What could go wrong
This is a small, completed study with only 60 participants. Adding epirubicin may increase side effects without clear benefit, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Aug 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:• Age group: Histologically diagnosed with primary endometrial carcinoma * more than 20 years old. * Any histological type of endometrial carcinoma * Stage III, IV * Stage one I or II with one or more of the following factors: 1. Histologic grade 3 endometroid carcinoma with myometrial invasion still within half of the myometrium 2. histological grade 1,2 endometroid carcinomas with invasion of over half of myometrium 3. cervical stromal invasion 4. vascular invasion; or 5. serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma * performance status 0-2 * adequate function of all major organs Exclusion Criteria: * • Pt has received prior radiation or chemotherapy. * Pt with sarcomatous component * Metastatic endometrial carcinoma * Other malignancy * Unfit patient for chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial carcinoma

Contacts and locations

Locations

  • Sohag university Hospital

    Sohag, Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.